- Home
- ITRM vs RIO Comparison
ITRM vs RIO Comparison
Compare ITRM & RIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRM
- RIO
- Stock Information
- Founded
- ITRM 2015
- RIO 1873
- Country
- ITRM Ireland
- RIO United Kingdom
- Employees
- ITRM N/A
- RIO N/A
- Industry
- ITRM Biotechnology: Pharmaceutical Preparations
- RIO Metal Mining
- Sector
- ITRM Health Care
- RIO Basic Materials
- Exchange
- ITRM Nasdaq
- RIO Nasdaq
- Market Cap
- ITRM 37.7M
- RIO N/A
- IPO Year
- ITRM 2018
- RIO N/A
- Fundamental
- Price
- ITRM $1.26
- RIO $60.56
- Analyst Decision
- ITRM Strong Buy
- RIO Buy
- Analyst Count
- ITRM 1
- RIO 4
- Target Price
- ITRM $5.00
- RIO $73.00
- AVG Volume (30 Days)
- ITRM 382.6K
- RIO 3.9M
- Earning Date
- ITRM 05-12-2025
- RIO 02-19-2025
- Dividend Yield
- ITRM N/A
- RIO 6.63%
- EPS Growth
- ITRM N/A
- RIO 14.71
- EPS
- ITRM N/A
- RIO 7.07
- Revenue
- ITRM N/A
- RIO $53,658,000,000.00
- Revenue This Year
- ITRM N/A
- RIO $1.59
- Revenue Next Year
- ITRM $150.10
- RIO $1.48
- P/E Ratio
- ITRM N/A
- RIO $8.93
- Revenue Growth
- ITRM N/A
- RIO N/A
- 52 Week Low
- ITRM $0.81
- RIO $51.67
- 52 Week High
- ITRM $3.02
- RIO $74.24
- Technical
- Relative Strength Index (RSI)
- ITRM 52.71
- RIO 55.38
- Support Level
- ITRM $1.01
- RIO $57.86
- Resistance Level
- ITRM $1.42
- RIO $61.88
- Average True Range (ATR)
- ITRM 0.09
- RIO 1.60
- MACD
- ITRM 0.03
- RIO 0.68
- Stochastic Oscillator
- ITRM 60.98
- RIO 87.07
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.